Rigrodsky & Long, P.A. Files Class Action Suit Against Tetraphase Pharmaceuticals, Inc.

WILMINGTON, DE, / ACCESSWIRE / April 29, 2020 / Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders of Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company") (NASDAQ:TTPH) common stock in connection with the proposed acquisition of Tetraphase by AcelRx Pharmaceuticals, Inc. ("AcelRx") and Consolidation Merger Sub, Inc. ("Merger Sub"), announced on March 16, 2020 (the "Complaint"). The Complaint, which alleges violations of the Securities Exchange Act of 1934 against Tetraphase, its Board of Directors (the "Board"), AcelRx, and Merger Sub, is captioned Plumley v. Tetraphase Pharmaceuticals, Inc., Case No. 1:20-cv-00496 (D. Del.).

If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff's counsel, Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 300 Delaware Avenue, Suite 1220, Wilmington, DE 19801, by telephone at (888) 969-4242, by e-mail at info@rl-legal.com, or at https://www.rigrodskylong.com/cases-tetraphase-pharmaceuticals-inc,join.

On March 15, 2020, Tetraphase entered into an agreement and plan of merger (the "Merger Agreement") with AcelRx and Merger Sub. Pursuant to the terms of the Merger Agreement, shareholders of Tetraphase will receive 0.6303 shares of AcelRx common stock and one contingent value right for each share of Tetraphase common stock they own (the "Proposed Transaction").

Among other things, the Complaint alleges that, in an attempt to secure shareholder support for the Proposed Transaction, defendants issued materially incomplete disclosures in a Form S-4 Registration Statement (the "Registration Statement") filed with the United States Securities and Exchange Commission. The Complaint alleges that the Registration Statement omits material information with respect to, among other things, the Company's and AcelRx's financial projections and the analyses performed by Tetraphase's financial advisor. The Complaint seeks injunctive and equitable relief and damages on behalf of holders of Tetraphase common stock.

If you wish to serve as lead plaintiff, you must move the Court no later than June 29, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising. Prior results do not guarantee a similar outcome.

CONTACT: 

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll-Free)
(302) 295-5310
Fax: (302) 654-7530
info@rl-legal.com 
https://rl-legal.com

SOURCE: Rigrodsky & Long P.A.

ReleaseID: 587629